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Objectives: To study the risk factors and rate of progression of asymptomatic carotid stenosis in patients with peripheral
arterial occlusive disease.
Methods: Between July 1999 and September 2003, we studied consecutive patients referred to a vascular laboratory for
peripheral arterial occlusive disease who had not experienced neurologic symptoms within the previous 3 years. Carotid
duplex ultrasound scan (DUS) was performed at baseline and at 6 to 12-month intervals. The internal carotid artery peak
systolic velocity (PSV) was used to determine severity of carotid stenosis. Multilevel linear regression modeling (MLM)
was used to identify the rate of progression and risk factors for progression.
Results: For 614 consecutive patients, median follow-up by DUS was 30 (2-42) months. Patients were 73 10-years-old,
and 62% were men. Mean ankle-brachial index (ABI) was 0.79  0.24. The baseline prevalence of carotid stenosis >50%
(PSV >125 cm/second) was 22%. During follow-up, ipsilateral amaurosis fugax, transient ischemic attacks, and strokes
occurred in 3 (0.4%), 7 (1.1%), and 5 (0.8%) patients, respectively. Overall, there was little progression in carotid stenosis.
Female gender, low ABI, and smoking were risk factors for progression of disease regardless of severity of carotid stenosis.
Patients with >50% carotid stenosis were at greatest risk of progression if they continued smoking and were diabetic.
Prediction models for progression of carotid stenosis given a baseline PSV and patient risk factors were constructed.
Conclusion: There are few neurologic events in patients with asymptomatic carotid stenosis. The average rate of
progression of stenosis over 2 years is not significant but greater in diabetic patients with baseline stenosis >50% who
continue smoking. Rescreening by serial DUS should be limited to high-grade stenosis and follow-up performed at an
interval of 1-2 years. ( J Vasc Surg 2009;50:292-8.)For symptomatic carotid stenosis, randomized con-
trolled trials have documented the benefit of prophylactic
carotid endarterectomy (CEA).1,2 The publication of
asymptomatic carotid artery trials3,4 have demonstrated a
small but statistically significant reduction in stroke follow-
ing carotid endarterectomy for asymptomatic patients. This
resulted in an increased interest in identification of asymp-
tomatic patients. The prevalence of moderate-to-severe
internal carotid artery stenosis is low in unselected elderly
(70-years-old) healthy volunteers (1.5%).5 Patients with
known peripheral vascular disease, however, have an in-
creased prevalence (32-33%) of hemodynamically signifi-
cant (50%) stenosis by duplex ultrasound scan (DUS).6,7
Because of its sensitivity and specificity,8,9 and the absence
of direct risk, DUS is a useful diagnostic test. Controversy
remains regarding the natural history of asymptomatic ca-
rotid stenosis, and, therefore, regarding the need for mon-
itoring with repeated DUS and the appropriate interval for
reassessment. We followed a large cohort of asymptomatic
patients with DUS for assessment of progression of carotid
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292stenosis, and with clinical evaluation for definition of neu-
rologic events, to provide information on the natural his-
tory of the disease.
Our group previously identified risk factors for carotid
stenosis in this population and examined progression of
carotid stenosis over a 6-9-month period.6 In this work, we
present the long-term follow-up (median 30 months) of
the same patient cohort with assessment of the risk and rate
of progression of stenosis and the occurrence of neurologic
symptoms with usual medical management.
METHODS
This is a prospective cohort study of patients, referred
by generalists or vascular surgeons, for assessment of lower
extremity peripheral arterial occlusive disease to a vascular
laboratory accredited by the Intersocietal Commission for
the Accreditation of Vascular Laboratory (ICAVL). In
addition to the noninvasive hemodynamic testing re-
quested by the referring physician, all patients also under-
went carotid duplex ultrasound scans. All results were
reported to the referring physician, but no attempt was
made to alter management.
Inclusion and exclusion criteria. Consecutive pa-
tients referred for noninvasive evaluation of lower-extremity
peripheral arterial occlusive disease on the basis of clinical
findings were included in the study. Patients were excluded
if they had neurologic symptoms or a documented neuro-
logic event within 3 years before entering the study. Arter-
ies were excluded from analysis if they were occluded, an
accurate DUS assessment was not available, or if they had
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Patients were excluded from the study if both arteries were
occluded.
Data collection. A registered vascular technologist,
trained in the assessment of clinical variables by study
physicians, administered a standard questionnaire to record
demographic data, details of pre-existing risk factors (gen-
der, age, diabetes mellitus, history of smoking, hyperten-
sion, prior stroke, and prior coronary artery disease), and
clinical outcomes of stroke, transient ischemic attack, am-
aurosis fugax, and carotid endarterectomy, at each visit. In
order to address bias resulting from the collection of clinical
outcomes from patients returning for repeat studies (events
might be more common in those who did not return), we
selected all participants with either artery having greater
than 50% stenosis who had not returned for follow-up
in the last 12 months of the study for extended clinical
follow-up by telephone. Calls were made by one of the
physician investigators. Resources did not permit telephone
follow-up of all patients who were not seen in the last 12
months of the study.
DUS. A DUS of the carotid arteries was done at the
time of entry in the study and repeated at 6 to 12-month
intervals by a registered vascular technologist. Color duplex
scanning was used to investigate the carotid arteries with a
5 MHz pulsed Doppler carrier, a 1.5 mm cubed sample
volume at a 60 degree angle to the axis of the vessel. The
internal carotid artery (ICA) and common carotid artery
(CCA) peak systolic velocity (PSV) and ICA/CCA ratio
were recorded. Carotid stenosis was determined according
to Strandness criteria10 and previously described classifica-
tion.9 All results were reported to the referring physicians.
Outcomes and statistical analysis. The primary out-
come was progression of carotid stenosis. Studies of this
outcome usually use one of the following approaches: (1)
Report results for the total number of carotids (right and
left); (2) Provide results for right or left carotid arteries
separately (considering the artery as the unit of analysis);
and (3) Provide results by most severe stenosis (considering
the patient as the unit of analysis). It is clear that the first
approach is flawed since findings of stenosis in the two
carotid arteries of the same patient are not independent
observations (an individual has unique properties that affect
the progression and presentation of carotid disease); the
second and the third approach do not take advantage of the
information derived by pooling the total number of carotid
arteries available to the researcher. We have addressed this
issue using multilevel linear regression modeling (MLM),
also known as linear mixed modeling. This is a multivariate
analytic technique which takes into consideration the rela-
tionships of the two carotid arteries within the same patient
and at different time points during the follow-up.11 MLM
explicitly recognizes the clustering of two arteries within
each individual and the correlation between them (ie, does
not treat them as independent observations). It also allows
evaluation of continuous variables with respect to time, and
to detect the rate of change within the artery. While life-
table analysis is limited to binary assessment of a categorical,MLM does not have any threshold limitation for assess-
ment of the variable under study.
For MLM, the ICA PSV was used to define the severity
of carotid stenosis.9 Since the relationship between the ICA
PSV ratio and angiographic-defined carotid stenosis by
NASCET is not linear (ie, one unit at the bottom of the
scale does not correspond to a percentage stenosis similar to
that of one unit at the top of the scale), we used the
logarithm of the ICA PSV as a dependent variable for
progression of stenosis in the MLM.
All patients with one or more follow-up ultrasound
scans were included in the analysis of progression of degree
of carotid stenosis. The variables studied were age, gender,
smoking history, current smoking, diabetes, hypertension,
coronary artery disease, history of stroke, and change in
ankle/brachial index (ABI). Data from arteries were cen-
sored in the MLM if they reached occlusion, an ipsilateral
neurologic event occurred, or if the patient underwent
CEA on that side. Clinically important variables or variables
that were statistically significant in univariate analysis were
entered into a multivariate analysis. Variables were retained
in the model if they were significant at the P  .05 level.
Regression models were created to predict the severity
of carotid stenosis (dependent variable) over 24 months
given the degree of baseline stenosis and presence of risk
factors. The following formula was used for the prediction
model (n  number of months): Log PSVtime n months 
ßtime  (n months)  ßRisk Factor a  ßRisk Factor b 
ßtime*Risk Factor a  (n months)  ßtime*Risk Factor b  (n
months). Data were analyzed using the statistical software
SPSS, version 10 (SPSS Inc, Chicago, Ill). Continuous
variables are expressed as mean  standard deviation.
RESULTS
Population characteristics. From July 1999 to De-
cember 2003, 614 patients met eligibility criteria and un-
derwent at least one duplex scan. (Our previous report is of
620 patients;6 on independent review of eligibility criteria
by two authors, 6 patients in the original study did notmeet
inclusion criteria.) Of this patient population, 547 (89.1%)
received at least one follow-up scan and provided data to
Table 1. Risk factors for atherosclerotic disease
Mean  SD; N (%)
Age 72.8  9.5
Male gender 370 (62)
Smoking history 489 (82)
Current smoking 137 (23)
Diabetes 133 (22)
Hypertension 417 (70)
Angina 288 (48)
Myocardial infarction 157 (26)
Remote stroke
†
85 (14)
Ankle brachial index 0.79  0.2
SD, Standard deviation; N, number.
†More than 3 years before entering the study.the analysis of progression of degree of stenosis. The base-
locity
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and antiplatelet medication status were unavailable for 158
and 132 patients, respectively. For the remainder of pa-
tients, 298 (65%) received lipid control medication, 411
(85%) received antiplatelet medication, and 231 (57%)
received both.
Degree of carotid stenosis. Severity of carotid steno-
sis was determined according to previously published crite-
ria.9 Of the 614 patients, 29 (2%) arteries were occluded,
40 (3%) had prior endarterectomy. There were 1159 arter-
ies eligible for study. Distribution of peak systolic velocity is
shown in the Fig.
Ultrasound follow-up. Of the 614 patients originally
recruited, 547 received at least one follow-up scan, 490
patients two, 350 patients three, 157 patients four, and 49
patients five. Themedian period of follow-up by ultrasound
scan was 30 (minimum 2, maximum 42) months.
Clinical follow-up. Of the 614 patients, 312 (51%)
were last assessed within the last 12 months of the study
with DUS and clinical examination. Of the remaining 302
patients, 102 had stenosis 50%: a physician investigator
contacted each patient by phone. Of these, 55 were alive
and well, 4 had died from stroke (details could not be
obtained from the families), 25 died from causes other than
strokes, and 18 died from unknown causes. The remaining
200 (33%) patients had no follow-up during the last 12
months of the study because the degree of stenosis did not
warrant further follow-up.
During follow-up, 10 (1.6%) patients experienced a
non-focal transient neurologic event. Symptoms included
speech problems, bilateral visual defects, and dizziness.
Focal right hemispheric transient ischemic attacks (TIAs)
Fig. Distribution of peak systolic veoccurred in 4 patients (0.6%) and 3 patients (0.5%) experi-enced left hemispheric TIAs, two of which led to CEA.
Three patients experienced amaurosis fugaux (0.5%).
From phone interviews, in addition to the four fatal
strokes, 6 patients had experienced non-fatal strokes, but
could not adequately describe their symptoms to identify
the affected side; medical records for these patients were
not available. There were three right hemispheric and two
left hemispheric strokes recorded from patients assessed in
the laboratory. One right hemispheric stroke occurred after
an angiography, a second was a complication of CEA.
During follow-up, 20 patients underwent CEA, one was
prompted by amaurosis fugax, and two were after TIAs.
Distribution of neurologic events with respect to baseline
stenosis 50% is displayed in Table II. The rate of neuro-
logic events was not statistically different between the two
groups.
Progression of carotid stenosis for 0-99% stenosis.
As shown in the Fig, most arteries did not have significant
carotid stenosis (PSV 125 corresponding to stenosis
50%). In these models, when all carotid arteries within
the cohort were studied, history of smoking, currently
smoking, female gender, and a decrease in ABI, were
associated with progression of carotid stenosis (Table III).
In the absence of these risks, average progression did not
occur. Examples of average progression of carotid stenosis
over 24 months for people with different combinations of
these risk factors is given in Table IV. The following for-
mula was used for the prediction model (n  number of
months): Log PSVtime n months  ßtime  (n months) 
ßcurrent smoking ßgender ßhistory smoking ßchange in ABI
(change in ABI)  ßtime*current smoking  (n months) 
in 1159 arteries eligible for study.ßtime*gender  (n months)  ßtime*history smoking 
or gr
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in ABI).
Progression of carotid stenosis for 50-99% stenosis.
Progression of disease in arteries with significant baseline
stenosis (50%) was associated with currently smoking and
diabetes (Table V); as in the previous model, there was no
average progression in the absence of these risk factors.
Examples of average progression for different combinations
Table II. Distribution of ipsilateral neurologic events acco
of the event could be determined
Baseline stenosis Stroke (%) TIA (%
50% 5/900 (0.5) 3/900 (
50% 0/259 (0) 4/200 (
Ten additional patients were found to have had a stroke (4 fatal, 6 non-fatal
laterality of the stroke could not be determined. The unit of analysis is arte
TIA, Transient ischemic attack; AMF, amaurosis fugaux.
*P  .05 for the proportion of events associated with arteries with less than
Table III. Risk factors for progression of carotid stenosis
Independent variable Beta
Intercept 1.940
Time (in months) 7.52  10
Currently smoking (yes) 1.82  10
Female gender (yes) 3.48  10
Smoking history (yes) 6.12  10
Change in ankle/brachial index over two interval
observations (each 0.2 decrease) 1.27  10
TimeCurrently Smoking 1.01  10
TimeFemale gender 5.96  10
TimeSmoking history 7.96  10
TimeChange in ankle/brachial index 1.13  10
The dependent variable peak systolic velocity (PSV) was log transformed be
other variables in the model, for each unit change (months for time; change
the other risk factors. Antilog beta shows the model parameter for average d
are constructed by taking antilog (beta 1.96 standard error) for each variab
with baseline stenosis. The effect size and statistical significance of the variabl
stenosis. Because of the log transformation in the model, this is multiplicat
current smokers at baseline).
Table IV. Model predictions for progression of carotid st
Baseline PSV
(cm/second) Female gender History of smoking
75 Y Y
75 Y Y
75 Y Y
75 Y N
75 N N
125 Y Y
125 Y Y
125 Y Y
125 Y N
125 N N
PSV, Peak systolic velocity; ABI, ankle brachial index; Y, yes; N, no.of risk factors are given in Table VI. The following formulawas used to derive model predictions: Log PSVtime n months
ßtime  (n months)  ßcurrent smoking  ßdiabetes 
ßtime*current smoking  (n months)  ßtime*diabetes  (n
months).
There were few patients who suffered a neurologic
event. The small size of this group did not permit a mean-
ingful comparison of progression of stenosis between pa-
tients who developed a neurologic event and those that
g to baseline stenosis for patients in whom the laterality
AMF (%) All neurologic events (%)
1/900 (0.1) 9/900 (1.0)*
2/259 (2.6) 9/259 (2.6)
ephone follow-up, but the association with artery could not be made as the
eater than 50% stenosis.
baseline 0-99% stenosis
Standard error Antilog beta
95% Confidence
intervals for
antilog beta P value
1.86  102 87.1 80.1 94.7 .001
3.10  104 0.998 0.997 1.000 .012
1.74  102 0.959 0.887 1.037 .295
1.56  102 1.008 0.939 1.082 .824
1.91  102 1.151 1.056 1.255 .001
3.17  102 0.746 0.647 0.861 .001
2.63  104 1.002 1.001 1.004 .001
2.20  104 1.001 1.000 1.002 .007
3.05  104 1.002 1.000 1.003 .009
4.72  104 0.997 0.995 1.000 .017
nalysis. Beta coefficients show the mean difference in log PSV, adjusted for
for change in ankle-brachial index) or for people with rather than without
ce in PSV for each unit change in a risk factor. The 95% confidence intervals
e effect size and statistical significance for each variable reflects its association
e interaction are themeasures of their association with progression of carotid
, multiply baseline stenosis by 1.002 for each month, in people who were
s 0-99% over 2 years
Current smoker
Decrease in ABI
(each 0.2 decrease)
PSV at 2 years
cm/second
Y Y 77
Y N 82
N N 79
N N 76
N N 72
Y Y 128
Y N 136
N N 131
N N 126
N N 119rdin
)
0.3)
2)
) in tel
ry.with
4
2
3
2
1
3
4
4
3
fore a
in 0.2
ifferen
le. Th
e tim
ive (ieenosiremained asymptomatic. During follow-up, carotid steno-
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ated with a neurologic event.
DISCUSSION
This study prospectively followed progression of ca-
rotid stenosis and neurologic events in 614 patients with
peripheral vascular disease (PVD). Patients were represen-
tative of people with PVD: they were mostly hypertensive
men with prior history of smoking, diabetes, and coronary
artery disease (Table I). Overall, there was little progression
of carotid stenosis. Female gender, history of smoking,
currently smoking, and decrease in ABI were risk factors for
progression of carotid stenosis when the cohort was as-
sessed as a group. The rate of progression, however, was
modest. However, patients with clinically significant base-
line stenosis (50%) who were diabetic and continued to
smoke experienced an average progression of degree of
stenosis that was clinically important over a 2-year time
frame (Table VI). These patients may warrant periodic
follow-up as they approach the threshold of benefit from
CEA; the optimal frequency of this follow-up remains to be
defined.12,13
We recognize several important limitations to our
study. This is a study of progression in people with amodest
prevalence of severe stenosis (6% had 70% carotid steno-
sis) and should not be generalized to people with high
degrees of stenosis at baseline.
We assembled a cohort at high-risk for carotid stenosis
based on referral for peripheral vascular studies, but did not
document the clinical degree of severity of the peripheral
Table V. Risk factors for progression of carotid stenosis fr
Independent variable Beta Standard er
Intercept 2.28 1.86  10
Time (months) 4.28  106 3.06  10
Currently smoking 3.49  102 2.59  10
Diabetes 2.41  102 2.55  10
Timecurrently smoking 1.95  103 5.68  10
Timediabetes 1.29  103 6.15  10
Table VI. Model predictions of progression of carotid
stenosis from baseline 50-99% over 2 years
Baseline PSV
(cm/second)
Current
smoker Diabetes
PSV at 2 years
(cm/second)
175 Y Y 209
175 Y N 195
175 N Y 187
175 N N 175
250 Y Y 299
250 Y N 279
250 N Y 269
250 N N 250
PSV, Peak systolic velocity.vascular symptoms, and were, therefore, unable to includethis in our analysis. Some patients included will undoubt-
edly have been referred for vascular studies for symptoms
not due to PVD.
While ultrasonographic scan follow-up was good, with
89% of patients returning for at least one follow-up exam-
ination and contributing to the analysis of progression of
stenosis, clinical follow-up, a secondary aim of this study,
was less complete. We recognized that the low event rate in
people returning for follow-up (5 strokes in 547 patients
[1%] over median 30-months of follow-up) might result
from biased ascertainment, since people with fatal stroke
were missed and people with stroke might be less likely to
return for routine follow-up. We selected 102 patients at
highest risk, based on a last recorded stenosis of 50% or
more, of the 302 people who had not returned for follow-up
in the last 12 months. Of these, 4 patients had died from
stroke and a further 6 had experienced stroke (10%), bear-
ing out our hypothesis. A sensitivity analysis accounting for
a similar stroke rate in the 200 people not evaluated in the
last 12months of the study would give an overall stroke rate
for the cohort of 35 strokes in 614 patients (5.7%); if the
stroke rate in the 200 people not contacted were more in
keeping with those that returned (1%), there would have
been 17 strokes in 614 patients (2.8%).
Our approach of censoring at stroke, TIA, or carotid
endarterectomy is, of course, statistically biased towards
under-estimation of progression. Those very people who
have had events, or whose physician has determined that
the benefits now exceed the risks of carotid endarterec-
tomy, are those who are most likely to progress. There is no
alternative but to censor after carotid endarterectomy, as
the anatomy is fundamentally altered by this procedure. We
chose to censor after stroke and TIA because each of these
is a defining event that alters the patients’ status from
asymptomatic to symptomatic. Once a patient develops
symptomatic disease, the issue of following for progression
of asymptomatic stenosis is no longer relevant and a differ-
ent question of whether the patient will likely benefit or not
benefit from endarterectomy on the basis of current severity
of stenosis in the affected artery instead needs to be an-
swered. For this reason, we felt that our censoring plan was
the most relevant to inform clinical practice in the moni-
toring of asymptomatic stenosis.
Our models estimate average progression; it is not
possible from this approach to estimate proportions pro-
aseline 50-99% stenosis
Odds ratio
95% Confidence interval
for odds ratio P value
192.0 176.6 208.7 .001
1.000 0.998 1.001 .989
1.084 0.964 1.218 .179
1.056 0.942 1.186 .346
1.005 1.002 1.007 .001
1.003 1.000 1.005 .036om b
ror
2
4
2
2
4
4gressing in each category as we have in earlier work from
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observed provide no support for strategies of repeated
screening at intervals shorter than 2 years, particularly in the
case of people with baseline stenosis less than 50% or in
people without risks. In our models, both for people with
0-99% stenosis and for people with 50-99% stenosis, all of
the effect of time on progression is in the interaction terms
(time*risk factor); the multiplicative term for the effect of
time in the absence of risk factors is very close to unity in
bothmodels (Tables III and V), and this is illustrated in our
scenarios: people with no risk factors have average PSV at 2
years that is not different from baseline (Tables IV and VI).
The sample size of 1159 arteries represents one of the
largest cohorts of asymptomatic carotid stenosis that has
been studied. Prior studies of progression of asymptomatic
carotid stenosis have reported conflicting results. The rate
of progression has ranged from minimal to 9% per
year.14-20 Table VII demonstrates some of the variability
amongst the studies. The ICAVL accreditation status of
these laboratories is not reported.14-20 The variability in
results can be explained by differences in baseline stenosis
of studied populations, medical interventions, technique of
DUS assessment, and methods of statistical evaluation of
progression. Prior reports have relied upon life-table anal-
ysis to determine rate of progression.14,15,17-20 Progression
is defined as a change from a lower category to a higher
category of stenosis. Often these categories are based upon
the Strandness classification.10 There are several disadvan-
tages to this approach. In life-table analysis, subjects are
censored after they reach an endpoint, in this case progres-
sion. Subsequently, possible regression in follow-up exam-
ination is not detected. Regression rates as high as 20% in
arteries that have shown progression have been reported,
some of whichmay be biological, and some due to variation
Table VII. Progression of asymptomatic carotid stenosis
Author
N
arteries/patients Baseline stenosis
Follo
(yea
Rockman15 282/246 50-79% 3.2 
Liapis14 442/332, 66%
asymptomatic
31% 50% 3.
Sleight16 219/219 50-79% - n  110
(50%); 80-99% -
n  107 (49%)
4
Mansour17 458/244 50-79% 2.1 
Rosamund18 N/A/715 50% n  357 (50%);
50-79% n  207 (29%)
3.2 y
Garvey20 1470/905 22% 50% 2.5 y
Nehler19 434/263 60% 1.7 y
N/A, Not available.in measurement.16The reliability of DUS between and within the same
laboratories is variable.9,21-23 Correaveau et al21 have dem-
onstrated that there is poor interobserver agreement in
measurement of PSV. Admittedly, regression analysis relies
on PSV since it is a continuous variable. While there may be
random error within an individual measurement, it is ex-
pected through serial measurements of the same artery, that
random error would be reduced.24 MLM is able to adjust
for the variability between serial DUS, since, unlike life-
table analysis, patients are not censored at progression and
follow-up studies are included.
Life-table analysis is unable to describe the net change
in stenosis for the sample population. Life-table analysis of
progression will not describe or account for regression of
stenosis. This study used MLM which evaluates whether
there is an overall progression of stenosis. Our observation
of modest progression is similar to observations by Sleight
et al16 who prospectively followed 219 patients assigned to
the medical treatment arm of the Asymptomatic Carotid
Stenosis Trial (ACST) (Table VII). Patients received clin-
ical examination and duplex scanning at entry, 4 months
following randomization, and at 12-month intervals.
The median percentage stenosis was plotted against
time, and the authors did not notice any net change in
stenosis when it was categorized by either Strandness
classification or deciles of stenosis. In their report, all
instances of progression and regression were followed,
and patients regardless of type of change were censored
at 4 years. If their analysis was conducted through a
life-table method, where patients are censored at the first
instance of progression, 51 patients would have achieved
progression (resulting in a progression rate of 23% over 4
years). This would have ignored 45 patients who re-
gressed, and also 10 of the 51 patients who progressed,
Definition of progression Regression Progression
Progression to a higher
Strandness Category
N/A 1 year-4.9%; 3
years-16.7%; 5
years-26.5%
Progression to a higher decile
of stenosis
N/A Annual rate 2.8%
Progression to a higher
Strandness Category or
higher decile of stenosis
14% None
Progression to a higher
Strandness
category (80%)
N/A 15.5% over 2.1
years
Progression to a higher
Strandness category
(50%, or 80%).
Regression defined as no
progression.
9.1% 50% -19.5% over
2.3 years to 
50%; 50-79-
22.2% over 2
years to 80%
Progression to a higher
Strandness category
2.6% Annual rate 9.3%
Stenosis 60% N/A 4% over 18
monthsw-up
rs)
1.5
7
1.1
ears
ears
earsand on repeat DUS were found to have regressed. If the
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(45) are considered together, overall there is no signifi-
cant progression of disease.
This study is the first to use MLM to assess carotid
stenosis. The technique allows arteries from the same pa-
tient to be analyzed separately, yet the characteristics that
are unique to that patient and artery, are preserved.
Through MLM we were able to formulate equations to
determine the rate of progression of stenosis for a given
baseline stenosis and individual risk factors. We are not
aware of any other reports that have produced prediction
models of progression.
CONCLUSION
Asymptomatic carotid stenosis did not, on average,
progress rapidly in this patient cohort. Patients with base-
line stenosis50% who continue to smoke and are diabetic
are at increased risk of progression, and may benefit from
screening every 2 years. MLM is an effective novel and
appropriate statistical method for understanding the natu-
ral history of carotid stenosis.
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